OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
ReViral Raises $44 Million in Series C Financing
-
Prelude Therapeutics Announces Closing of $50M Series C Financing
-
Form SC 13G/A ESSA Pharma Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Acutus Medical, Inc. Filed by: ORBIMED ADVISORS LLC
-
Ikena Oncology Appoints Dr. Sergio Santillana, MD, MSc, MBA as Chief Medical Officer
-
Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
-
Form 4 Acutus Medical, Inc. For: Aug 10 Filed by: ORBIMED ADVISORS LLC
-
Ikena Oncology Announces Publication in Nature Communications of Preclinical Data Supporting the Therapeutic Potential of AHR Blockade
-
Form 4 Inspire Medical Systems, For: Aug 07 Filed by: ORBIMED ADVISORS LLC
-
Xtant Medical Announces Debt Restructuring
-
Form 3 Acutus Medical, Inc. For: Aug 05 Filed by: ORBIMED ADVISORS LLC
-
Natera Reports Second Quarter 2020 Financial Results
-
PMV Pharma Closes $70 Million in Series D Financing
-
Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Pandion Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form 3 Pandion Therapeutics, For: Jul 16 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A 89bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
-
Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External Innovation
-
Form SC 13D Fusion Pharmaceuticals Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Sinovac Reports Unaudited First Quarter 2020 Financial Results
-
Form SC 13D Compass Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Repare Therapeutics Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 3 Fusion Pharmaceuticals For: Jun 25 Filed by: ORBIMED ADVISORS LLC
-
Form 4 Compass Therapeutics, For: Jun 19 Filed by: ORBIMED ADVISORS LLC
-
Form 3 Compass Therapeutics, For: Jun 17 Filed by: ORBIMED ADVISORS LLC
-
Ikena Oncology Presents New Preclinical Data Highlighting the Anti-Cancer Effects of TEAD Inhibition on the Hippo Signaling Pathway
-
Form 3 Repare Therapeutics Inc. For: Jun 18 Filed by: ORBIMED ADVISORS LLC
-
Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer
-
Form SC 13D/A BELLUS Health Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Alector, Inc. Filed by: ORBIMED ADVISORS LLC
-
Q32 Bio Launches to Develop Novel Therapeutics Targeting Regulators of Innate and Adaptive Immunity
-
Form SC 13D/A scPharmaceuticals Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Turning Point Therapeuti Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
-
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
-
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results
-
Form 4 Xtant Medical Holdings, For: May 06 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
-
Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
-
9 Meters Biopharma, Inc Announces the Closing of Naia Rare Diseases Acquisition
-
Natera (NTRA) Tops Q1 EPS by 11c, Revenues Beat
-
Natera Reports First Quarter 2020 Financial Results
-
9 Meters Biopharma, Inc Announces the Closing of $22.5 Million Private Placement Funding
-
Form SC 13D Oric Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
9 Meters Biopharma, a Rare, Orphan and Unmet Needs GI-Focused Company, is Created with the Transformative Merger Between Innovate Biopharmaceuticals and RDD Pharma
-
Sinovac Reports Unaudited Fourth Quarter 2019 Financial Results and Files 2019 Annual Report on Form 20-F

